Journal of Antimicrobial Chemotherapy (2002) 49, 445-453
© 2002 The British Society for Antimicrobial Chemotherapy
Reviews |
Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime
a Cognigen Corporation, 395 Youngs Road, Buffalo, NY 14221-5831; b Maine Medical Center & University of Vermont, College of Medicine, 22 Bramhall Street, Portland, ME 04102-3175; c F. F. Thompson Hospital, 350 Parish Street, Canandiagua, NY 14424; d The Jones Group/JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
Pseudomonas aeruginosa is one of the more common and clinically difficult-to-treat causes of hospital-acquired infections. Cefepime is a broad-spectrum cephalosporin with potent in vitro activity against Gram-positive cocci, enteric Gram-negative bacilli and Pseudomonas aeruginosa. Cephalosporins exhibit time-dependent bactericidal activity and lack prolonged post-antibiotic effects against Enterobacteriaceae and P. aeruginosa. In non-clinical models of infection against Enterobacteriaceae and P. aeruginosa, antibacterial effects are observed when serum levels are above the MIC for as little as 35% of the dosing interval and are maximized when levels exceed the MIC for 60–70% of the dosing interval. Based on the MIC distribution for P. aeruginosa and pharmacokinetic data obtained from patients with serious bacterial infections (including pneumonia and sepsis), time above MIC targets can be met in infected patients following 2 g doses of cefepime administered every 12 h. An understanding of the integration of target patient population pharmacokinetics and the MIC distribution is crucial for selecting effective dosage regimens, especially in the setting of empirical therapy. Moreover, sufficient clinical outcome data in infected patients exist and support these pharmacodynamic conclusions.
* Corresponding author. Tel: +1-716-633-3463 ext 302; Fax: +1-716-633-7404; E-mail: paul.ambrose{at}cognigen.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. Koenig and J. D. Truwit Ventilator-Associated Pneumonia: Diagnosis, Treatment, and Prevention Clin. Microbiol. Rev., October 1, 2006; 19(4): 637 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Huang and M. J. Rybak Pharmacodynamics of Cefepime Alone and in Combination with Various Antimicrobials against Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model Antimicrob. Agents Chemother., January 1, 2005; 49(1): 302 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Masterton, J. L. Kuti, P. J. Turner, and D. P. Nicolau The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe J. Antimicrob. Chemother., January 1, 2005; 55(1): 71 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Mouton, A. Schmitt-Hoffmann, S. Shapiro, N. Nashed, and N. C. Punt Use of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141 Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1713 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Miyazaki, K. Okazaki, M. Tsuji, and K. Yamaguchi Pharmacodynamics of S-3578, a Novel Cephem, in Murine Lung and Systemic Infection Models Antimicrob. Agents Chemother., February 1, 2004; 48(2): 378 - 383. [Abstract] [Full Text] [PDF]
|
|